Genitourinary Cancer

Genitourinary Cancer

SS 08 - GU 2 - Long-Term Updates of Prospective Prostate Cancer Clinical Trials

10/22/2018
7:45 AM - 9:00 AM
Location: Room 214 C/D

Session Type: Scientific
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits

Presentations:

Drew Moghanaki, MD, MPH

Veterans Affairs - Richmond, VA

Disclosure:
Employment
Hunter Holmes McGuire Veterans Medical Center: Staff Physician: Employee; Virginia Commonwealth University: Associate Professor: Employee

Compensation
Bristol-Myers Squibb Foundation: Research Grants; Varian Medical Systems: Honoraria; Veterans Affairs Cooperative Studies Program: Research Grants

Leadership
Association of VA Hematology Oncology: Board member, Chair research committee; ASTRO: Chair; Lung Cancer Alliance: Medical and Professional Advisory Board; Lungevity Foundation: Scientific Advisory Board

Biography:
Drew Moghanaki, MD, MPH
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia - USA
@drewmoghanaki

I am a radiation oncologist who directs the clinical research program at the VA medical center in Richmond, Virginia. I have a passion for multi-disciplinary care, and thus serve as a member, scientific advisor, and chair of multiple national committees for the American Cancer Society, Lung Cancer Alliance, LUNGevity Foundation, and ASTRO. I am a co-chair for the VALOR phase III lung cancer Surgery vs SBRT trial, which is sponsored by the VA Cooperative Studies Program. I also am the principal investigator for the VA-PALS lung screening project which is adopitng the I-ELCAP management system for implementation at 10 VA medical centers to increase the number of lung cancer patients diagnosed at an early stage.


Presentation(s):

Send Email for Drew Moghanaki

Daniel Spratt, MD

University of Michigan

Disclosure:
Employment
The University of Michigan Cancer Center: Assistant Professor: Employee, Associate Professor: Employee

Biography:
Dan Spratt, MD, is an Associate Professor in the Department of Radiation Oncology at the University of Michigan. He is a national leader in genitourinary and spinal malignancies. In addition to his medical training at Vanderbilt University where he obtained his medical degree, he completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center. Dr. Spratt is the Chief of the Genitourinary Radiotherapy Program and Vice Chair of Clinical Research within the Department of Radiation Oncology. He also is the co-chair for the Genitourinary Division of Clinical Research for the Rogel Cancer Center, co-leader of the LAPS U10 cooperative group clinical trial program, is the founder and director the Spine Oncology Program at the University of Michigan, and co-chairs the radiobiology and radiotherapy working group for the Prostate Cancer Foundation. He gives talks nationally and internationally on his work in prostate cancer, and serves on study sections for several federal and foundation programs. Dr. Spratt has published extensively in peer-reviewed journals and has received grant funding on the topics of prostate cancer and spinal malignancies. He has developed novel prognostic models to assess the aggressiveness of a patient’s cancer using not only clinical and pathologic features, but also genomic and imaging biomarkers. His laboratory focuses on the interaction of androgens and DNA repair in prostate cancer and methods to overcome radiation resistance. He runs novel phase I/II clinical trials to improve treatment outcomes and reduce side effects from cancer treatment.

Presentation(s):

Send Email for Daniel Spratt


Assets

SS 08 - GU 2 - Long-Term Updates of Prospective Prostate Cancer Clinical Trials



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for SS 08 - GU 2 - Long-Term Updates of Prospective Prostate Cancer Clinical Trials